Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway

Figure 1

Effect of formononetin or formononetin plus everolimus on tumor outgrowth. (a) Mice were first injected with MDA-MB-468 cells for 2 weeks to establish the xenograft model. Mice were then administered formononetin (50 mg/kg), everolimus (2 mg/kg), or formononetin plus everolimus. After 4 weeks, mice were sacrificed and tumors were excised and weighed. p < 0.05 versus control. (b) Body weights of animals treated with formononetin or formononetin plus everolimus for 4 weeks.

(a)

(b)